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C L I N I C A L  I N Q U I R I E S
What is the target for low-density lipoprotein
cholesterol in patients with heart disease?
EVIDENCE-BASED ANSWER Large published ran-
domized controlled trials (RCTs) show that pravas-
tatin and simvastatin are well-tolerated and reduce
major coronary events
such as death, myocar-
dial infarction, and
revascularization by
about 25%. The Heart
Protection Study sug-
gested this benefit is
noted even among
individuals with pre-
treatment low-density
lipoprotein (LDL) cho-
lesterol of less than
100 mg/dL. Fluvastatin
reduces major coro-
nary events, but current studies are too small to
prove reduced overall mortality. The best evidence
to date suggests that most patients at significant risk
for major coronary events should be given pravas-
tatin or simvastatin 40 mg daily, without concern for
the initial or follow-up LDL levels. (Grade of recom-
mendation: A, based on large randomized trials.)
EVIDENCE SUMMARY The evidence is solid to
support the use of HMG–CoA reductase inhibitors
(statins) for patients with coronary artery disease
(CAD). The Scandinavian Simvastatin Survival study
used simvastatin 20 mg daily unless total cholesterol
levels did not decrease to less than 200 mg/dL.1 The
Long-Term Intervention with Pravastatin in Ischaemic
Disease study randomized patients to pravastatin 40
mg daily or placebo, without titration.2 The interven-
tion arm in the Cholesterol and Recurrent Events trial
was also pravastatin 40 mg daily, with cholestyra-
mine added if the LDL level remained higher than
175 mg/dL.3 The Lescol Intervention Prevention
study randomized patients after angioplasty to flu-
vastatin 40 mg twice daily or placebo.4 The Heart
Protection Study used simvastatin 40 mg daily, with-
out titration.5 No RCTs have evaluated the clinical
benefit of adding medications to adequate doses of
statins to lower LDL to less than 175 mg/dL. See
Table of major RCTs with clinical outcomes.
Subgroup analyses of earlier major RCTs had sug-
gested that patients with CAD and low initial LDL
levels (< 125 mg/dL) have little to gain from pravas-
tatin.2,3 However, the Heart Protection Study enrolled
20,000 people with CAD or equivalent (diabetes,
peripheral vascular disease, stroke, etc).5 The study
demonstrated a reduction of major coronary events
with simvastatin, with numbers needed to treat
(NNT) of 19 (P < .0001); the NNT for reduction in
all-cause mortality was 55 (P = .0003). The benefit of
simvastatin was noted in virtually every predefined
subgroup, including individuals older than 70 years,
women, and patients without known CAD (but with
CAD equivalents).
Notably, no difference in benefit was found
between patients with different pretreatment LDL
levels. A significant reduction in major vascular
events was noted even for the 3400 subjects with
pretreatment LDL levels of less than 100 mg/dL
(NNT = 22, P = .0006). A greater percentage reduc-
tion in LDL with medication did not predict better 
clinical outcomes.5 
RECOMMENDATIONS FROM OTHERS The National
Cholesterol Education Project (NCEP) recommends
that patients with CAD and an LDL of more than 130
mg/dL adopt therapeutic lifestyle changes and start
LDL-lowering medication, usually a statin. For
patients with LDL between 100 and 130 mg/dL, the
NCEP recommends therapeutic lifestyle changes,
with the option of adding a statin. For patients with
LDL less than 100 mg/dL, maintenance of LDL con-
trol is recommended with therapeutic lifestyle
changes. For patients with high initial LDL levels that
stay above 100 mg/dL on statin therapy, the NCEP
recommends that additional medications, such as
nicotinic acid or fibrates, as well as intensive thera-
peutic lifestyle changes, be considered.6
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TA B L E  
LDL levels and relative risk of major coronary events after treatment
Intervention LDL level, mg/dL Relative risk of major 
Study, year N medication Control group    Intervention group coronary events
4S,1 1994 4444 Simvastatin 20 mg/d* 190 122 0.66 (0.59–0.85)
CARE,3 1996 4159 Pravastatin 40 mg/d 139 97 0.76 (0.64–0.91)
LIPID,2 1998 9014 Pravastatin 40 mg/d 150 113 0.76 (0.68–0.85)
LIPS,4 2002 1677 Fluvastatin 80 mg/d 132 100 0.78 (0.64–0.95)
HPS,5 2002 20,536 Simvastatin 40 mg/d 127 89 0.76 (0.72–0.81)
*Increased to 40 mg/d if total cholesterol did not drop to less than 200 mg/dL.
4S, Scandinavian Simvastatin Survival Study; CARE, Cholesterol and Recurrent Events trial; HPS, Heart Protection Study; LDL, low-density 
lipoprotein; LIPID, Long-Term Intervention with Pravastatin in Ischaemic Disease study; LIPS, Lescol Intervention Prevention Study.
